Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-494 versus placebo and adalimumab in methotrexate-inadequate-response rheumatoid arthritis
NL-OMON44070Phase 3Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in rheumatoid arthritis (RA) (3 arms), sponsored by AbbVie Inc. Primary endpoints: ACR20 response at Week 12 and Clinical remission based on DAS28(CRP) at Week 12. Planned start Nov 2015; status: withdrawn.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON44070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44070.